Developing therapeutic strategies to promote myelin repair in multiple sclerosis

References

• Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247–269.
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(Pt 3):606–616.
   PubMed Web of Science ®Google Scholar
• Ontaneda D, Thompson AJ, Fox RJ, et al. Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Lancet. 2017;389(10076):1357–1366.
   PubMed Web of Science ®Google Scholar
• Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14(2):183–193.
   PubMed Web of Science ®Google Scholar
• Frohman EM, Racke MK, Raine CS. Multiple sclerosis–the plaque and its pathogenesis. N Engl J Med. 2006;354(9):942–955.
   PubMed Web of Science ®Google Scholar
• Prineas JW, Barnard RO, Revesz T, et al. Multiple sclerosis. Pathology of recurrent lesions. Brain. 1993;116(Pt 3):681–693.
   PubMedGoogle Scholar
• Plemel JR, Liu WQ, Yong VW. Remyelination therapies: a new direction and challenge in multiple sclerosis. Nat Rev Drug Discov. 2017;16(9):617–634.
   PubMed Web of Science ®Google Scholar
• Sim FJ, Zhao C, Penderis J, et al. The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. J Neurosci. 2002;22(7):2451–2459.
   PubMed Web of Science ®Google Scholar
• Franklin RJ, Goldman SA. Glia disease and repair-remyelination. Cold Spring Harb Perspect Biol. 2015;7(7):a020594.
   PubMed Web of Science ®Google Scholar
• Boyd A, Zhang H, Williams A. Insufficient OPC migration into demyelinated lesions is a cause of poor remyelination in MS and mouse models. Acta Neuropathol. 2013;125(6):841–859.
   PubMed Web of Science ®Google Scholar
• Yeung MSY, Djelloul M, Steiner E, et al. Dynamics of oligodendrocyte generation in multiple sclerosis. Nature. 2019;566(7745):538–542.
   PubMed Web of Science ®Google Scholar
• Jakel S, Agirre E, Mendanha Falcao A, et al. Altered human oligodendrocyte heterogeneity in multiple sclerosis. Nature. 2019;566(7745):543–547.
   PubMed Web of Science ®Google Scholar
• Fields RD. A new mechanism of nervous system plasticity: activity-dependent myelination. Nat Rev Neurosci. 2015;756–767. England.
   PubMed Web of Science ®Google Scholar
• Lampron A, Larochelle A. Laflamme N, et al. Inefficient clearance of myelin debris by microglia impairs remyelinating processes. J Exp Med. 2015;212(4):481–495.
   PubMed Web of Science ®Google Scholar
• Mayo L, Trauger SA, Blain M, et al. Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation. Nat Med. 2014;20(10):1147–1156.
   PubMed Web of Science ®Google Scholar
• Essuman K, Summers DW, Sasaki Y, et al. The SARM1 toll/interleukin-1 receptor domain possesses intrinsic NAD(+) cleavage activity that promotes pathological axonal degeneration. Neuron. 2017;93(6):1334–1343.e1335.
   PubMed Web of Science ®Google Scholar
• Mount CW, Monje M. Wrapped to adapt: experience-dependent myelination. Neuron. 2017;95(4):743–756.
   PubMed Web of Science ®Google Scholar
• Gautier HO, Evans KA, Volbracht K, et al. Neuronal activity regulates remyelination via glutamate signalling to oligodendrocyte progenitors. Nat Commun. 2015;6:8518.
   PubMed Web of Science ®Google Scholar
• Buckley C, Marguerie A, Roach A, et al. Drug reprofiling using zebrafish identifies novel compounds with potential pro-myelination effects. Neuropharmacology. 2010;59(3):149–159.
   PubMed Web of Science ®Google Scholar
• Deshmukh VA, Tardif V, Lyssiotis CA, et al. A regenerative approach to the treatment of multiple sclerosis. Nature. 2013;502(7471):327–332.
   PubMed Web of Science ®Google Scholar
• Mei F, Fancy SPJ, Shen YA, et al. Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nat Med. 2014;20(8):954–960.
   PubMed Web of Science ®Google Scholar
• Najm FJ, Madhavan M, Zaremba A, et al. Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo. Nature. 2015;522(7555):216–220.
   PubMed Web of Science ®Google Scholar
• Hubler Z, Allimuthu D, Bederman I, et al. Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination. Nature. 2018;560(7718):372–376.
   PubMed Web of Science ®Google Scholar
• Green AJ, Gelfand JM, Cree BA, et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet. 2017;390(10111):2481–2489.
   PubMed Web of Science ®Google Scholar
• Cohen JA. Mesenchymal stem cell transplantation in multiple sclerosis. J Neurol Sci. 2013;333(1–2):43–49.
   PubMed Web of Science ®Google Scholar
• Korbling M, Estrov Z. Adult stem cells for tissue repair - a new therapeutic concept? N Engl J Med. 2003;349(6):570–582.
   PubMed Web of Science ®Google Scholar
• Woodbury D, Schwarz EJ, Prockop DJ, et al. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res. 2000;61(4):364–370.
   PubMed Web of Science ®Google Scholar
• Scolding NJ, Pasquini M, Reingold SC, et al. Cell-based therapeutic strategies for multiple sclerosis. Brain. 2017;140(11):2776–2796.
   PubMed Web of Science ®Google Scholar
• Rajan TS, Giacoppo S, Diomede F, et al. The secretome of periodontal ligament stem cells from MS patients protects against EAE. Sci Rep. 2016;6:38743.
   PubMed Web of Science ®Google Scholar
• Zhang J, Li Y, Chen J, et al. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol. 2005;195(1):16–26.
   PubMed Web of Science ®Google Scholar
• Rice CM, Scolding NJ. Adult human mesenchymal cells proliferate and migrate in response to chemokines expressed in demyelination. Cell Adh Migr. 2010;4(2):235–240.
   PubMed Web of Science ®Google Scholar
• Lee RH, Pulin AA, Seo MJ, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009;5(1):54–63.
   PubMed Web of Science ®Google Scholar
• Anderson P, Gonzalez-Rey E, O’Valle F, et al. Allogeneic adipose-derived mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by regulating self-reactive T cell responses and dendritic cell function. Stem Cells Int. 2017;2389753:2017.
   Google Scholar
• Yang H, Sun J, Wang F, et al. Umbilical cord-derived mesenchymal stem cells reversed the suppressive deficiency of T regulatory cells from peripheral blood of patients with multiple sclerosis in a co-culture - a preliminary study. Oncotarget. 2016;7(45):72537–72545.
   PubMedGoogle Scholar
• Ma OK, Chan KH. Immunomodulation by mesenchymal stem cells: interplay between mesenchymal stem cells and regulatory lymphocytes. World J Stem Cells. 2016;8(9):268–278.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Imrey PB, Planchon SM, et al. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Mult Scler J. 2018;24(4): 501–511.
   Google Scholar
• Connick P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012;11(2):150–156.
   PubMed Web of Science ®Google Scholar
• Llufriu S, Sepulveda M, Blanco Y, et al. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PloS One. 2014;9(12):e113936.
   PubMed Web of Science ®Google Scholar
• Odinak MM, Bisaga GN, Novitskii AV, et al. Transplantation of mesenchymal stem cells in multiple sclerosis. Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(2 Pt 2):72–76.
   PubMedGoogle Scholar
• Bonab MM, Sahraian MA, Aghsaie A, et al. Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study. Curr Stem Cell Res Ther. 2012;7(6):407–414.
   PubMed Web of Science ®Google Scholar
• Mohyeddin Bonab M, Yazdanbakhsh S, Lotfi J. et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iran J Immunol. 2007;4(1):50–57.
   PubMedGoogle Scholar
• Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010;67(10):1187–1194.
   PubMed Web of Science ®Google Scholar
• Yamout B, Hourani R, Salti H, et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. J Neuroimmunol. 2010;227(1–2):185–189.
   PubMed Web of Science ®Google Scholar
• Harris VK, Stark J, Vyshkina T, et al. Phase I trial of intrathecal mesenchymal stem cell-derived neural progenitors in progressive multiple sclerosis. EBioMedicine. 2018Feb3;29:23–30. Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Harris VK, Vyshkina T, Sadiq SA. Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis. Cytotherapy. 2016;18(12):1476–1482.
   PubMed Web of Science ®Google Scholar
• Li JF, Zhang DJ, Geng T, et al. The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis. Cell Transplant. 2014;23(Suppl 1):S113–122.
   PubMed Web of Science ®Google Scholar
• Liang J, Zhang H, Hua B, et al. Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis. Mult Scler. 2009;15(5):644–646.
   PubMed Web of Science ®Google Scholar
• Lublin FD, Bowen JD, Huddlestone J, et al. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study. Mult Scler Relat Disord. 2014;3(6):696–704.
   PubMed Web of Science ®Google Scholar
• Berkowitz AL, Miller MB, Mir SA, et al. Glioproliferative Lesion of the Spinal Cord as a Complication of “Stem-Cell Tourism”. N Engl J Med. 2016;375(2):196–198.
   PubMed Web of Science ®Google Scholar
• Baldassari LE, Cohen JA. Mesenchymal stem cell-derived neural progenitor cells in progressive multiple sclerosis: great expectations. EBioMedicine. 2018;29:5–6.
   PubMed Web of Science ®Google Scholar
• Uccelli A, Laroni A, Brundin L, et al. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials. 2019;20(1):263.
   PubMedGoogle Scholar
• Heidker RM, Emerson MR, LeVine SM. Metabolic pathways as possible therapeutic targets for progressive multiple sclerosis. Neural Regen Res. 2017;12(8):1262–1267.
   PubMed Web of Science ®Google Scholar
• Sedel F, Bernard D, Mock DM, et al. Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis. Neuropharmacology. 2016;110(Pt B):644–653.
   PubMedGoogle Scholar
• Tourbah A, Lebrun-Frenay C, Edan G, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Mult Scler. 2016;22(13):1719–1731.
   PubMed Web of Science ®Google Scholar
• Heidker RM, Emerson MR, LeVine SM. Intersections of pathways involving biotin and iron relative to therapeutic mechanisms for progressive multiple sclerosis. Discov Med. 2016;22(123):381–387.
   PubMed Web of Science ®Google Scholar
• Sedel F, Papeix C, Bellanger A, et al. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord. 2015;4(2):159–169.
   PubMed Web of Science ®Google Scholar
• Birnbaum G, Stulc J. High dose biotin as treatment for progressive multiple sclerosis. Mult Scler Relat Disord. 2017;18:141–143.
   PubMed Web of Science ®Google Scholar
• Mi S, Miller RH, Lee X, et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci. 2005;8(6):745–751.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang YP, Pepinsky B, et al. Inhibition of LINGO-1 promotes functional recovery after experimental spinal cord demyelination. Exp Neurol. 2015;266:68–73.
   PubMed Web of Science ®Google Scholar
• Mi S, Hu B, Hahm K, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med. 2007;13(10):1228–1233.
   PubMed Web of Science ®Google Scholar
• Cadavid D, Balcer L, Galetta S, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16(3):189–199.
   PubMed Web of Science ®Google Scholar
• McCroskery P, Selmaj K, Fernandez O, et al. Safety and tolerability of opicinumab in relapsing multiple sclerosis: the phase 2b SYNERGY trial (P5.369). Neurology. 2017;88(16Suppl).
   Google Scholar
• Mellion M, Edwards K, Hupperts R, et al. Efficacy results from the phase 2b SYNERGY study: treatment of disabling multiple sclerosis with the anti-LINGO-1 monoclonal antibody opicinumab (S33.004). In: American Academy of Neurology. Boston, MA. 2017.
   Google Scholar
• Mellion M, Edwards K, Hupperts R, et al. Additional efficacy analyses from the phase 2b SYNERGY study investigating the anti-LINGO-1 monoclonal antibody opicinumab for treatment of disabling multiple sclerosis (P5.337). In: American Academy of Neurology. Boston, MA. 2017.
   Google Scholar
• Sheikh S, Calabresi P, Giovannoni G, et al. Predictors of an opicinumab treatment effect and identification of an efficacy subpopulation: a post hoc analysis of the SYNERGY study (P3.408). In: American Academy of Neurology Annual Meeting. Los Angeles, CA. 2018.
   Google Scholar
• Zhornitsky S, Johnson TA, Metz LM, et al. Prolactin in combination with interferon-beta reduces disease severity in an animal model of multiple sclerosis. J Neuroinflammation. 2015;12:55.
   PubMed Web of Science ®Google Scholar
• Zhornitsky S, Wee Yong V, Koch MW, et al. Quetiapine fumarate for the treatment of multiple sclerosis: focus on myelin repair. CNS Neurosci Ther. 2013;19(10):737–744.
   PubMed Web of Science ®Google Scholar
• Hartley MD, Banerji T, Tagge IJ, et al. Myelin repair stimulated by CNS-selective thyroid hormone action. JCI Insight. 2019;4:8.
   Web of Science ®Google Scholar
• Zhang M, Ma Z, Qin H, et al. Thyroid hormone potentially benefits multiple sclerosis via facilitating remyelination. Mol Neurobiol. 2016;53(7):4406–4416.
   PubMed Web of Science ®Google Scholar
• Hussain R, Ghoumari AM, Bielecki B, et al. The neural androgen receptor: a therapeutic target for myelin repair in chronic demyelination. Brain. 2013;136(Pt 1):132–146.
   PubMed Web of Science ®Google Scholar
• Barkhof F, Calabresi PA, Miller DH, et al. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol. 2009;5(5):256–266.
   PubMed Web of Science ®Google Scholar
• Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577–589.
   PubMed Web of Science ®Google Scholar
• Hardmeier M, Leocani L, Fuhr P. A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS. Mult Scler J. 2017;23(10):1309–1319.
   Google Scholar
• Hardmeier M, Hatz F, Naegelin Y, et al. Improved characterization of visual evoked potentials in multiple sclerosis by topographic analysis. Brain Topogr. 2014;27(2):318–327.
   PubMed Web of Science ®Google Scholar
• van Diemen HA, Polman CH, van Dongen TM, et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol. 1992;32(2):123–130.
   PubMed Web of Science ®Google Scholar
• Fujihara K, Miyoshi T. The effects of 4-aminopyridine on motor evoked potentials in multiple sclerosis. J Neurol Sci. 1998;159(1):102–106.
   PubMed Web of Science ®Google Scholar
• Sormani M, Bruzzi P. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol. 2013;12(7):669–676.
   PubMed Web of Science ®Google Scholar
• Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008;131(Pt 3):808–817.
   PubMed Web of Science ®Google Scholar
• Miller DH, Rudge P, Johnson G, et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain. 1988;111(Pt 4):927–939.
   PubMedGoogle Scholar
• Kaunzner UW, Gauthier SA. MRI in the assessment and monitoring of multiple sclerosis: an update on best practice. Ther Adv Neurol Disord. 2017;10(6):247–261.
   PubMed Web of Science ®Google Scholar
• Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol. 2002;15(3):239–245.
   PubMed Web of Science ®Google Scholar
• Meier DS, Guttmann CR. Time-series analysis of MRI intensity patterns in multiple sclerosis. Neuroimage. 2003;20(2):1193–1209.
   PubMed Web of Science ®Google Scholar
• Meier DS, Weiner HL, Guttmann CR. MR imaging intensity modeling of damage and repair in multiple sclerosis: relationship of short-term lesion recovery to progression and disability. AJNR Am J Neuroradiol. 2007;28(10):1956–1963.
   PubMed Web of Science ®Google Scholar
• Vavasour IM, Laule C, Li DK, et al. Is the magnetization transfer ratio a marker for myelin in multiple sclerosis? J Magn Reson Imaging. 2011;33(3):713–718.
   PubMed Web of Science ®Google Scholar
• Schmierer K, Scaravilli F, Altmann DR, et al. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol. 2004;56(3):407–415.
   PubMed Web of Science ®Google Scholar
• Filippi M, Iannucci G, Tortorella C, et al. Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. Neurology. 1999;52(3):588–594.
   PubMed Web of Science ®Google Scholar
• Barkhof F, Bruck W, De Groot CJ, et al. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol. 2003;60(8):1073–1081.
   PubMedGoogle Scholar
• Chen JT, Collins DL, Atkins HL, et al. Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol. 2008;63(2):254–262.
   PubMed Web of Science ®Google Scholar
• Chen JT, Collins DL, Freedman MS, et al. Local magnetization transfer ratio signal inhomogeneity is related to subsequent change in MTR in lesions and normal-appearing white-matter of multiple sclerosis patients. NeuroImage. 2005;25(4):1272–1278.
   PubMed Web of Science ®Google Scholar
• Fernández O, Izquierdo G, Fernández V, et al. Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study. PloS One. 2018;13:e0195891.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Coffey CS, Conwit R, et al. Phase 2 trial of ibudilast in progressive multiple sclerosis. N Engl J Med. 2018;379(9):846–855.
   PubMed Web of Science ®Google Scholar
• Romme Christensen J, Ratzer R, Bornsen L, et al. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial. Neurology. 2014;82(17):1499–1507.
   PubMed Web of Science ®Google Scholar
• Gareau PJ, Rutt BK, Karlik SJ, et al. Magnetization transfer and multicomponent T2 relaxation measurements with histopathologic correlation in an experimental model of MS. J Magn Reson Imaging. 2000;11(6):586–595.
   PubMed Web of Science ®Google Scholar
• Berry I, Barker GJ, Barkhof F, et al. A multicenter measurement of magnetization transfer ratio in normal white matter. J Magn Reson Imaging. 1999;9(3):441–446.
   PubMed Web of Science ®Google Scholar
• Giacomini PS, Levesque IR, Ribeiro L, et al. Measuring demyelination and remyelination in acute multiple sclerosis lesion voxels. Arch Neurol. 2009;66(3):375–381.
   PubMedGoogle Scholar
• Oh S, Lowe M. Segmented EPI readout variable flip-angle magnetization transfer (EP-vfMT) imaging for 7T quantitative MT (qMT) imaging. In: 25th Scientific Meeting, International Society for Magnetic Resonance in Medicine. Honolulu, HI. 2017.
   Google Scholar
• MacKay AL, Laule C. Magnetic resonance of myelin water: an in vivo marker for myelin. Brain Plast. 2016;2(1):71–91.
   PubMedGoogle Scholar
• Laule C, Vavasour IM, Moore GR, et al. Water content and myelin water fraction in multiple sclerosis. A T2 relaxation study. J Neurol. 2004;251(3):284–293.
   PubMed Web of Science ®Google Scholar
• Vavasour IM, Huijskens SC, Li DK, et al. Global loss of myelin water over 5 years in multiple sclerosis normal-appearing white matter. Mult Scler. 2018;24(12):1557–1568.
   PubMed Web of Science ®Google Scholar
• Vargas WS, Monohan E, Pandya S, et al. Measuring longitudinal myelin water fraction in new multiple sclerosis lesions. Neuroimage Clin. 2015;9:369–375.
   PubMed Web of Science ®Google Scholar
• Vavasour IM, Laule C, Li DK, et al. Longitudinal changes in myelin water fraction in two MS patients with active disease. J Neurol Sci. 2009;276(1–2):49–53.
   PubMed Web of Science ®Google Scholar
• Laule C, Leung E, Lis DK, et al. Myelin water imaging in multiple sclerosis: quantitative correlations with histopathology. Mult Scler. 2006;12(6):747–753.
   PubMed Web of Science ®Google Scholar
• Vavasour IM, Tam R, Li DK, et al. A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab. Mult Scler J. 2019;25(6):811–818.
   Google Scholar
• Vavasour I. Monitoring myelin changes using advanced magnetic resonance imaging in multiple sclerosis patients treated with ocrelizumab over 48 months. In: ECTRIMS. Berlin, Germany. 2019.
   Google Scholar
• Levesque IR, Pike GB. Characterizing healthy and diseased white matter using quantitative magnetization transfer and multicomponent T(2) relaxometry: A unified view via a four-pool model. Magn Reson Med. 2009;62(6):1487–1496.
   PubMed Web of Science ®Google Scholar
• Webb S, Munro CA, Midha R, et al. Is multicomponent T2 a good measure of myelin content in peripheral nerve? Magn Reson Med. 2003;49(4):638–645.
   PubMed Web of Science ®Google Scholar
• Prasloski T, Rauscher A, MacKay AL, et al. Rapid whole cerebrum myelin water imaging using a 3D GRASE sequence. NeuroImage. 2012;63(1):533–539.
   PubMed Web of Science ®Google Scholar
• Deoni SC, Rutt BK, Arun T, et al. Gleaning multicomponent T1 and T2 information from steady-state imaging data. Magn Reson Med. 2008;60(6):1372–1387.
   PubMed Web of Science ®Google Scholar
• Oh SH, Bilello M, Schindler M, et al. Direct visualization of short transverse relaxation time component (ViSTa). NeuroImage. 2013;83:485–492.
   PubMed Web of Science ®Google Scholar
• Oh SH, Choi JY, Im Y, et al. Myelin water fraction of the whole brain: 3D GRASE MWI vs. 3D ViSTa MWI. In: 23rd Scientific Meeting, International Society for Magnetic Resonance in Medicine. Toronto, Canada. 2014.
   Google Scholar
• Fox RJ. Picturing multiple sclerosis: conventional and diffusion tensor imaging. Semin Neurol. 2008;28(4):453–466.
   PubMed Web of Science ®Google Scholar
• Klawiter EC, Schmidt RE, Trinkaus K, et al. Radial diffusivity predicts demyelination in ex vivo multiple sclerosis spinal cords. NeuroImage. 2011;55(4):1454–1460.
   PubMed Web of Science ®Google Scholar
• Harrison DM, Caffo BS, Shiee N, et al. Longitudinal changes in diffusion tensor-based quantitative MRI in multiple sclerosis. Neurology. 2011;76(2):179–186.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Cronin T, Lin J, et al. Measuring myelin repair and axonal loss with diffusion tensor imaging. AJNR Am J Neuroradiol. 2011;32(1):85–91.
   PubMed Web of Science ®Google Scholar
• Naismith RT, Xu J, Tutlam NT, et al. Increased diffusivity in acute multiple sclerosis lesions predicts risk of black hole. Neurology. 2010;74(21):1694–1701.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Sakaie K, Lee JC, et al. A validation study of multicenter diffusion tensor imaging: reliability of fractional anisotropy and diffusivity values. AJNR Am J Neuroradiol. 2012;33(4):695–700.
   PubMed Web of Science ®Google Scholar
• Jespersen SN, Bjarkam CR, Nyengaard JR, et al. Neurite density from magnetic resonance diffusion measurements at ultrahigh field: comparison with light microscopy and electron microscopy. NeuroImage. 2010;49(1):205–216.
   PubMed Web of Science ®Google Scholar
• Grussu F, Schneider T, Tur C, et al. Neurite dispersion: a new marker of multiple sclerosis spinal cord pathology? Ann Clin Transl Neurol. 2017;4(9):663–679.
   PubMed Web of Science ®Google Scholar
• Schneider T, Brownlee W, Zhang H, et al. Sensitivity of multi-shell NODDI to multiple sclerosis white matter changes: a pilot study. Funct Neurol. 2017;32:97–101.
   PubMed Web of Science ®Google Scholar
• De Santis S, Bastiani M, Droby A, et al. Characterizing microstructural tissue properties in multiple sclerosis with diffusion MRI at 7T and 3T: the impact of the experimental design. Neuroscience. 2019;403:17–26.
   Web of Science ®Google Scholar
• Granberg T, Fan Q, Treaba CA, et al. In vivo characterization of cortical and white matter neuroaxonal pathology in early multiple sclerosis. Brain. 2017;140:2912–2926.
   PubMed Web of Science ®Google Scholar
• Zhang H, Schneider T, Wheeler-Kingshott CA, et al. NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain. NeuroImage. 2012;61(4):1000–1016.
   PubMed Web of Science ®Google Scholar
• Kwong KK, Belliveau JW, Chesler DA, et al. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acad Sci U S A. 1992;89(12):5675–5679.
   PubMed Web of Science ®Google Scholar
• Enzinger C, Pinter D, Rocca MA, et al. Longitudinal fMRI studies: exploring brain plasticity and repair in MS. Mult Scler. 2016;22(3):269–278.
   PubMed Web of Science ®Google Scholar
• Audoin B, Ibarrola D, Ranjeva JP, et al. Compensatory cortical activation observed by fMRI during a cognitive task at the earliest stage of MS. Hum Brain Mapp. 2003;20(2):51–58.
   PubMed Web of Science ®Google Scholar
• Cader S, Cifelli A, Abu-Omar Y, et al. Reduced brain functional reserve and altered functional connectivity in patients with multiple sclerosis. Brain. 2006;129(Pt 2):527–537.
   PubMedGoogle Scholar
• Sajja BR, Wolinsky JS, Narayana PA. Proton magnetic resonance spectroscopy in multiple sclerosis. Neuroimaging Clin N Am. 2009;19(1):45–58.
   PubMed Web of Science ®Google Scholar
• Tartaglia MC, Narayanan S, De Stefano N, et al. Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis. J Neurol. 2002;249(10):1382–1390.
   PubMed Web of Science ®Google Scholar
• Ross B, Bluml S. Magnetic resonance spectroscopy of the human brain. Anat Rec. 2001;265(2):54–84.
   PubMedGoogle Scholar
• Moccia M, Molecular CO. Metabolic imaging in multiple sclerosis. Neuroimaging Clin N Am. 2017;27(2):343–356.
   PubMed Web of Science ®Google Scholar
• Prinsen H, de Graaf RA, Mason GF, et al. Reproducibility measurement of glutathione, GABA, and glutamate: towards in vivo neurochemical profiling of multiple sclerosis with MR spectroscopy at 7 tesla. J Magn Reson Imaging. 2017;45(1):187–198.
   PubMed Web of Science ®Google Scholar
• Azevedo CJ, Kornak J, Chu P, et al. In vivo evidence of glutamate toxicity in multiple sclerosis. Ann Neurol. 2014;76(2):269–278.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wu C, Caprariello AV, et al. In vivo quantification of myelin changes in the vertebrate nervous system. J Neurosci. 2009;29(46):14663–14669.
   PubMed Web of Science ®Google Scholar
• Klunk WE, Wang Y, Huang GF, et al. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci. 2001;69(13):1471–1484.
   PubMed Web of Science ®Google Scholar
• Stankoff B, Freeman L, Aigrot MS, et al. Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl-(1)(1)C]-2-(4ʹ-methylaminophenyl)- 6-hydroxybenzothiazole. Ann Neurol. 2011;69(4):673–680.
   PubMed Web of Science ®Google Scholar
• Bodini B, Veronese M, Garcia-Lorenzo D, et al. Dynamic imaging of individual remyelination profiles in multiple sclerosis. Ann Neurol. 2016;79(5):726–738.
   PubMed Web of Science ®Google Scholar
• Wu C, Zhu J, Baeslack J, et al. Longitudinal positron emission tomography imaging for monitoring myelin repair in the spinal cord. Ann Neurol. 2013;74(5):688–698.
   PubMed Web of Science ®Google Scholar
• Balcer LJ, Miller DH, Reingold SC, et al. Vision and vision-related outcome measures in multiple sclerosis. Brain. 2015;138(Pt 1):11–27.
   PubMed Web of Science ®Google Scholar
• Klistorner A, Arvind H, Garrick R, et al. Remyelination of optic nerve lesions: spatial and temporal factors. Mult Scler. 2010;16(7):786–795.
   PubMed Web of Science ®Google Scholar
• Ciccarelli O, Cohen JA, Reingold SC, et al. Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurol. 2019;18(2):185–197.
   PubMed Web of Science ®Google Scholar
• Leocani L, Rovaris M, Boneschi FM, et al. Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study. J Neurol Neurosurg Psychiatry. 2006;77:1030–1035.
   PubMed Web of Science ®Google Scholar
• Schlaeger R, D’Souza M, Schindler C, et al. Electrophysiological markers and predictors of the disease course in primary progressive multiple sclerosis. Mult Scler. 2014;20(1):51–56.
   PubMed Web of Science ®Google Scholar
• Richert ND, Ostuni JL, Bash CN, et al. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Mult Scler. 2001;7(1):49–58.
   PubMed Web of Science ®Google Scholar
• Dalton CM, Miszkiel KA, Barker GJ, et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol. 2004;251(4):407–413.
   PubMed Web of Science ®Google Scholar
• Nash RA, Hutton GJ, Racke MK, et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology. 2017;88(9):842–852.
   PubMed Web of Science ®Google Scholar
• Miller DH, Fox RJ, Phillips JT, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology. 2015;84(11):1145–1152.
   PubMed Web of Science ®Google Scholar
• Altmann DR, Button T, Schmierer K, et al. Sample sizes for lesion magnetisation transfer ratio outcomes in remyelination trials for multiple sclerosis. Mult Scler Relat Disord. 2014;3(2):237–243.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23(8):1123–1136.
   PubMed Web of Science ®Google Scholar
• Wilhelm MJ, Ong HH, Wehrli SL, et al. Direct magnetic resonance detection of myelin and prospects for quantitative imaging of myelin density. Proc Natl Acad Sci U S A. 2012;109(24):9605–9610.
   PubMed Web of Science ®Google Scholar
• Oh J, Bakshi R, Calabresi PA, et al. The NAIMS cooperative pilot project: design, implementation and future directions. Mult Scler. 2018;24(13):1770–1772.
   PubMed Web of Science ®Google Scholar